Addex Therapeutics Ltd (NASDAQ:ADXN) Short Interest Down 73.9% in September

Addex Therapeutics Ltd (NASDAQ:ADXN) was the recipient of a large decline in short interest in September. As of September 15th, there was short interest totalling 25,400 shares, a decline of 73.9% from the August 31st total of 97,500 shares. Currently, 3.1% of the company’s stock are sold short. Based on an average daily trading volume, of 277,000 shares, the days-to-cover ratio is presently 0.1 days.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and issued a $30.00 price objective on shares of Addex Therapeutics in a report on Wednesday, August 28th.

Addex Therapeutics Price Performance

Shares of ADXN stock opened at $9.63 on Friday. Addex Therapeutics has a 12 month low of $5.00 and a 12 month high of $27.90. The firm has a market capitalization of $10.21 million, a P/E ratio of -0.56 and a beta of 1.80. The company’s fifty day moving average price is $9.04 and its two-hundred day moving average price is $10.65.

About Addex Therapeutics

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder.